Evidence map›Paper›PMID 37875544›Full record

ArticleScientific reports2023

Phage activity against Staphylococcus aureus is impaired in plasma and synovial fluid.

Michele Mutti, David Sáez Moreno, Marcela Restrepo-Córdoba, Zehra Visram, Grégory Resch, Lorenzo Corsini

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. mSphere · 2026
    Article
  5. Review
  6. Bacteriophage-mediated reduction of uropathogenicbioRxiv : the preprint server for biology · 2025
    Article
  7. Article
  8. Article
  9. Phage SEP1 hijacksmSystems · 2024
    Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Michele Mutti *BioNTech R&D Austria GmbH, Vienna, Austria.
David Sáez Moreno *BioNTech R&D Austria GmbH, Vienna, Austria.
Marcela Restrepo-CórdobaBioNTech R&D Austria GmbH, Vienna, Austria.
Zehra VisramBioNTech R&D Austria GmbH, Vienna, Austria.
Grégory ReschCenter for Research and Innovation in Clinical Pharmaceutical Sciences (CRISP), Lausanne Hospital (CHUV), Lausanne, Switzerland.
Lorenzo CorsiniBioNTech R&D Austria GmbH, Vienna, Austria. lorenzo.corsini@biontech.at.
AustriaTech (Austria) · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

S. aureus is a pathogen that frequently causes severe morbidity and phage therapy is being discussed as an alternative to antibiotics for the treatment of S. aureus infections. In this in vitro and animal study, we demonstrated that the activity of anti-staphylococcal phages is severely impaired in 0.5% plasma or synovial fluid. Despite phage replication in these matrices, lysis of the bacteria was slower than phage propagation, and no reduction of the bacterial population was observed. The inhibition of the phages associated with a reduction in phage adsorption, quantified to 99% at 10% plasma. S. aureus is known to bind multiple coagulation factors, resulting in the formation of aggregates and blood clots that might protect the bacterium from the phages. Here, we show that purified fibrinogen at a sub-physiological concentration of 0.4 mg/ml is sufficient to impair phage activity. In contrast, dissolution of the clots by tissue plasminogen activator (tPA) partially restored phage activity. Consistent with these in vitro findings, phage treatment did not reduce bacterial burdens in a neutropenic mouse S. aureus thigh infection model. In summary, phage treatment of S. aureus infections inside the body may be fundamentally challenging, and more investigation is needed prior to proceeding to in-human trials.

Indexed as

Staphylococcal InfectionsStaphylococcus aureusAnimalsAnti-Bacterial AgentsHumansMiceStaphylococcus PhagesSynovial FluidTissue Plasminogen ActivatorAnti-Bacterial AgentsTissue Plasminogen Activator

Identifiers

PMID37875544
PMCPMC10598271
OpenAlexW4387902002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.